APIMEDS PHARMACEUTICALS US, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 15.40 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 159.48M shares, a 31209.14% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 509.37K shares, a 2.47% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 497.09K shares.
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 159.48M shares, a 31392.39% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 506.40K shares, a 2.95% increase from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 491.88K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 15.40M shares 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | 159.48M shares 10-Q · filed 2026-05-26 | ||||
| 2025-12-31 | 159.48M shares 10-K · filed 2026-05-04 | ||||
| 2025-09-30 | 961.12K shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 126.54K shares 10-Q · filed 2026-08-14 | 758.62K shares 10-Q · filed 2025-08-19 | |||
| 2025-03-31 | 509.37K shares 10-Q · filed 2026-05-26 | ||||
| 2024-12-31 | 506.40K shares 10-K · filed 2025-04-15 | ||||
| 2024-09-30 | 497.09K shares 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | 497.09K shares 10-Q · filed 2025-08-19 | ||||
| 2024-03-31 | 497.09K shares 10-Q · filed 2025-05-20 | ||||
| 2023-12-31 | 491.88K shares 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |